上海医药
上海醫藥
상해의약
Shanghai Medical & Pharmaceutical Journal
2015年
21期
3-5,31
,共4页
乳腺癌%分子靶向治疗%人表皮生长因子受体2
乳腺癌%分子靶嚮治療%人錶皮生長因子受體2
유선암%분자파향치료%인표피생장인자수체2
breast cancer%molecular targeted therapy%HER2
人表皮生长因子受体2（HER2）阳性乳腺癌进展快，预后差。但随着曲妥珠单抗等分子靶向药物的临床应用，显著改善了HER2阳性乳腺癌患者的疗效。本文总结了HER2标准检测和分子靶向药物在HER2阳性乳腺癌治疗中的临床应用策略及治疗进展。
人錶皮生長因子受體2（HER2）暘性乳腺癌進展快，預後差。但隨著麯妥珠單抗等分子靶嚮藥物的臨床應用，顯著改善瞭HER2暘性乳腺癌患者的療效。本文總結瞭HER2標準檢測和分子靶嚮藥物在HER2暘性乳腺癌治療中的臨床應用策略及治療進展。
인표피생장인자수체2（HER2）양성유선암진전쾌，예후차。단수착곡타주단항등분자파향약물적림상응용，현저개선료HER2양성유선암환자적료효。본문총결료HER2표준검측화분자파향약물재HER2양성유선암치료중적림상응용책략급치료진전。
The progression of the human epidermal growth factor receptor 2 (HER2)-positive breast cancer is rapid with poor prognosis. However, with clinical application of molecular targeted drugs such as trastuzumab and so on, their efifcacy in patients with HER2-positive breast cancer has been signiifcantly improved. The strategies and treatment progress for clinical application of the standard test of HER2 and molecular targeted drugs in the treatment of HER2-positive breast cancer are summarized.
